Trizepatide 60MG

TIRZEPATIDE | Dual-Incretin Metabolic Research

Exploring the Science of GIP & GLP-1 Signaling

Tirzepatide is a dual GIP and GLP-1 receptor agonist that acts on two important incretin pathways involved in glucose regulation, appetite signaling, and energy balance. It has become a significant area of research in metabolic and cardiometabolic science.

Clinical research has evaluated tirzepatide for glycemic control and chronic weight management. In the United States, tirzepatide is FDA-approved under different brand names for specific medical indications, including type 2 diabetes and chronic weight management.

Research Focus

• GIP receptor signaling
• GLP-1 receptor signaling
• Glucose and insulin regulation
• Appetite and energy-balance pathways
• Metabolic health
• Body-weight research

Clinical Status: FDA-approved prescription medication for specific indications. Tirzepatide-containing compounded products are not FDA-approved, and marketing them as equivalent to FDA-approved products can create regulatory issues.

Important: Tirzepatide carries important safety warnings and contraindications, including a boxed warning concerning thyroid C-cell tumors observed in rats and contraindication for individuals with a personal or family history of medullary thyroid carcinoma or MEN 2.